Athira Issues Statement in Response to Richard A. Kayne's Suspension of His Proxy ContestGlobeNewsWire • 05/16/22
Ric Kayne Suspends Campaign to Elect Himself and George Bickerstaff to Athira Pharma Board of DirectorsBusiness Wire • 05/16/22
Ric Kayne Issues Letter to Athira Shareholders Highlighting Need for Immediate Change to Athira BoardBusiness Wire • 05/12/22
Athira Urges Shareholders to Support its Director Nominees at May 19 Annual MeetingGlobeNewsWire • 05/11/22
ATHIRA PHARMA INVESTIGATION CONTINUED By Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Athira Pharma, Inc. - ATHABusiness Wire • 05/05/22
Leading Independent Proxy Advisory Firm Glass Lewis Recommends that Athira Shareholders Vote “FOR” All of Athira's Highly Qualified Director NomineesGlobeNewsWire • 05/05/22
Leading Proxy Advisory Firm ISS Recommends Athira Shareholders “Withhold” Support From Incumbent Directors Joseph Edelman and John FlukeBusiness Wire • 05/05/22
Leading Independent Proxy Advisory Firm ISS Recommends that Athira Shareholders Vote on Athira's WHITE Proxy CardGlobeNewsWire • 05/04/22
Ric Kayne Issues Letter to Athira Shareholders Highlighting Why Immediate Board Change Is RequiredBusiness Wire • 04/27/22
Ric Kayne Publishes Investor Presentation Highlighting Urgent Need for Changes to Athira's Board of DirectorsBusiness Wire • 04/25/22
Athira Mails Letter to Shareholders Highlighting the Strength of its Board and Record of Deliberate Board RefreshmentGlobeNewsWire • 04/20/22
ATHIRA ALERT: Bragar Eagel & Squire, P.C. is Investigating Athira Pharma, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the FirmBusiness Wire • 04/16/22
Athira Pharma Highlights Strong Execution of Strategy and Positioning for the FutureGlobeNewsWire • 03/30/22
Is Athira Pharma, Inc. (ATHA) Outperforming Other Medical Stocks This Year?Zacks Investment Research • 03/30/22
Ric Kayne and Affiliates Confirm Nomination of Two Highly Qualified Candidates for Election to Athira Pharma's Board of DirectorsBusiness Wire • 03/30/22
Athira Pharma, Inc. (ATHA) CEO Mark Litton on Q4 2021 Results - Earnings Call TranscriptSeeking Alpha • 03/24/22
Athira Pharma Reports Full Year 2021 Financial Results and Provides Clinical UpdateGlobeNewsWire • 03/24/22
Athira Pharma Announces Appointment of Dr. Michael A. Panzara to its Board of DirectorsGlobeNewsWire • 03/21/22
Athira Pharma Presents Study Overview and Baseline Data from ACT-AD Phase 2 Trial of Fosgonimeton in Mild-to-Moderate Alzheimer's Disease at the 2022 AD/PD™ CongressGlobeNewsWire • 03/20/22
Athira Pharma to Present Overview and Update from ACT-AD Phase 2 Trial of Fosgonimeton (ATH-1017) in Mild-to-Moderate Alzheimer's Disease at AD/PD™ 2022 CongressGlobeNewsWire • 03/14/22
Athira Pharma Presents Preclinical Data of Fosgonimeton (ATH-1017) and ATH-1020 at the American Society for Experimental Neurotherapeutics (ASENT) Annual MeetingGlobeNewsWire • 03/02/22